Death toll from coronaviruses in France exceeds 23,000


PARIS (Reuters) – France has become the fourth country to report more than 23,000 coronavirus-related deaths on Monday, while the number of new confirmed cases has increased at its fastest pace in almost two weeks.

The latest figures from the Ministry of Health arrive one day before Prime Minister Edouard Philippe presents to Parliament the government’s plan to untie the national lock which has been in place since March 17 and is due to expire on May 11.

The number of people hospitalized with COVID-19 – the lung disease caused by the new coronavirus – fell for the 13th consecutive day to 28055, while the number of people in intensive care decreased for the 19th consecutive year to 4608.

But the number of deaths increased by 437 to 23,293, its highest rate of increase in four days. And the total number of confirmed cases increased by 3,764 to 128,339. This 3% increase was the highest since April 14.

The number of probable cases in nursing homes is more or less stable at 37,503, for an overall total of confirmed and probable cases of 165,842 cases.

In its press release, the Ministry of Health also mentioned “promising results” in a clinical trial conducted by the CHU AP-HP, involving tocilizumab, used in the treatment of rheumatoid arthritis.

The 129 patients involved in the trial were selected on the basis of hospitalization for moderate or severe COVID-19 pneumonia, but did not require resuscitation at the time of admission.

“It has been established that patients treated with tocilizumab have a reduced need for ventilation and a lower mortality rate after 14 days of treatment,” said the Ministry of Health, adding that the results would be submitted for publication in a journal at reading committee.

“Le is the first drug tested where a positive effect is observed in a clinical trial. “

Regeneron Pharmaceuticals (REGN.O) and Sanofi (SASY.PA) said on Monday that the results of a study on their rheumatoid arthritis drug, Kevzara, indicated that it could only help the sickest coronavirus patients, which dampened the hope that the drug could benefit a larger group of infected people.

Report by Benoit Van Overstraeten; Editing by Chris Reese and Alex Richardson

Our standards:Principles of the Thomson Reuters Trust.


Please enter your comment!
Please enter your name here